Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia
PURPOSE OF REVIEW: This is a comprehensive review of the literature regarding the use of Lumateperone tosylate for schizophrenia. This review presents the background, evidence, and indications for the use of lumateperone tosylate in the treatment of schizophrenia.
RECENT FINDINGS: Schizophrenia is a chronic mental health disorder that affects approximately 3.3 million people in the United States. Its symptoms, which must be present more than six months, are comprised of disorganized behavior and speech, a diminished capacity to comprehend reality, hearing voices unheard by others, seeing things unseen by others, delusions, decreased social commitment, and decreased motivation. The majority of these symptoms can be managed with antipsychotic medication. Lumateperone is a selective and concurrent modulator of serotonin, dopamine, and glutamate, which all mediate or modulate serious mental illness.
SUMMARY: Schizophrenia is a complex, severe mental illness that affects how the brain processes information. There are many medications used to treat schizophrenia. One antipsychotic agent, lumateperone tosylate, is a newer agent that the FDA recently approved. The most common adverse effects are shown to be mild such as somnolence, constipation, sedation, and fatigue, with the 42 mg recommended dose. Lumateperone tosylate is an FDA-approved drug that can be given only at the 42mg dose once daily with no titration requirements.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Health psychology research - 9(2021), 1 vom: 26., Seite 24932 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maini, Kunal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Caplyta |
|---|
| Anmerkungen: |
Date Revised 28.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.52965/001c.24932 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332845362 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332845362 | ||
| 003 | DE-627 | ||
| 005 | 20231225220420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.52965/001c.24932 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332845362 | ||
| 035 | |a (NLM)34746489 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maini, Kunal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a PURPOSE OF REVIEW: This is a comprehensive review of the literature regarding the use of Lumateperone tosylate for schizophrenia. This review presents the background, evidence, and indications for the use of lumateperone tosylate in the treatment of schizophrenia | ||
| 520 | |a RECENT FINDINGS: Schizophrenia is a chronic mental health disorder that affects approximately 3.3 million people in the United States. Its symptoms, which must be present more than six months, are comprised of disorganized behavior and speech, a diminished capacity to comprehend reality, hearing voices unheard by others, seeing things unseen by others, delusions, decreased social commitment, and decreased motivation. The majority of these symptoms can be managed with antipsychotic medication. Lumateperone is a selective and concurrent modulator of serotonin, dopamine, and glutamate, which all mediate or modulate serious mental illness | ||
| 520 | |a SUMMARY: Schizophrenia is a complex, severe mental illness that affects how the brain processes information. There are many medications used to treat schizophrenia. One antipsychotic agent, lumateperone tosylate, is a newer agent that the FDA recently approved. The most common adverse effects are shown to be mild such as somnolence, constipation, sedation, and fatigue, with the 42 mg recommended dose. Lumateperone tosylate is an FDA-approved drug that can be given only at the 42mg dose once daily with no titration requirements | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a caplyta | |
| 650 | 4 | |a lumateperone tosylate | |
| 650 | 4 | |a schizophrenia | |
| 650 | 4 | |a schizophrenia treatment | |
| 700 | 1 | |a Hollier, Janice W |e verfasserin |4 aut | |
| 700 | 1 | |a Gould, Haley |e verfasserin |4 aut | |
| 700 | 1 | |a Bollich, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a John LaForge, John |e verfasserin |4 aut | |
| 700 | 1 | |a Cornett, Elyse M |e verfasserin |4 aut | |
| 700 | 1 | |a Edinoff, Amber N |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Adam M |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Health psychology research |d 2013 |g 9(2021), 1 vom: 26., Seite 24932 |w (DE-627)NLM243870574 |x 2420-8124 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:1 |g day:26 |g pages:24932 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.52965/001c.24932 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 1 |b 26 |h 24932 | ||